Updated Jul 16, 2026
Francois Cedric has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $10.54M.
Cedric Francois is the Chief Executive Officer and a Director of Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies to treat diseases through complement inhibition. He has played a significant role in advancing the company's innovative treatment approaches.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 196.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 98.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 36.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 20.9K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 196.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 196.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 98.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 98.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 87.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 87.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 143.8K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 143.8K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 234.4K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 300.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 472.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 372.8K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 426.0K | — | |
| 2026-03-13 | APLS | Apellis Pharmaceuticals, Inc. | G — Bona-fide gift | 64.9K | $0.00 | |
| 2026-03-13 | APLS | Apellis Pharmaceuticals, Inc. | G — Bona-fide gift | 64.9K | $0.00 | |
| 2026-02-05 | APLS | Apellis Pharmaceuticals, Inc. | M — Option exercise | 8.8K | $3.76 | $33K |
Cedric Francois is the Chief Executive Officer and a Director of Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies to treat diseases through complement inhibition. He has played a significant role in advancing the company's innovative treatment approaches.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($10.54M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Francois Cedric profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.